Next Article in Journal
Reproducibility Assessment of Enzyme-Linked Immunosorbent Assays to Detect Anti-HPV16 L1-Specific IgG1, IgG3, IgA, and IgM Antibodies
Previous Article in Journal
Immune Responses to Methicillin-Resistant Staphylococcus aureus Infections and Advances in the Development of Vaccines and Immunotherapies
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 12
Issue 10
10.3390/vaccines12101107
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States

by
Hagit Kopel
1,
Van Hung Nguyen
2,
Alina Bogdanov
3,
Isabelle Winer
3,
Catherine Boileau
2,
Thierry Ducruet
2,
Ni Zeng
3,
Jessamine P. Winer-Jones
3,
Daina B. Esposito
1,
Mary Bausch-Jurken
1,
Ekkehard Beck
1,
Machaon Bonafede
3 and
James A. Mansi
1,*
1
Moderna, Inc., Cambridge, MA 02139, USA
2
VHN Consulting Inc., Montreal, QC H2V 3L8, Canada
3
Veradigm, Chicago, IL 60654, USA
*
Author to whom correspondence should be addressed.
Vaccines 2024, 12(10), 1107; https://doi.org/10.3390/vaccines12101107
Submission received: 23 August 2024 / Revised: 16 September 2024 / Accepted: 23 September 2024 / Published: 27 September 2024
(This article belongs to the Section COVID-19 Vaccines and Vaccination)
Browse Figures
Versions Notes

Abstract

Background/Objectives: This retrospective cohort study evaluated the relative vaccine effectiveness (rVE) of two bivalent (original/Omicron BA.4/BA.5) vaccines mRNA-1273.222 versus the BNT162b2 Bivalent in preventing COVID-19-related outcomes in adults with underlying medical conditions associated with increased risk for severe COVID-19. Methods: In a linked electronic health record/claims dataset, US adults (≥18 years) with ≥1 underlying medical condition of interest who received either the bivalent vaccine between 31 August 2022 and 28 February 2023 were identified. The inverse probability of treatment weighting was used to adjust for cohort differences. Cohorts were followed up for COVID-19-related hospitalizations and outpatient encounters until 31 May 2023. Hazard ratios and rVEs were estimated using Cox regression. Subgroup analyses were performed on individuals with pre-specified comorbid conditions. Results: 757,572 mRNA-1273.222 and 1,204,975 BNT162b2 Bivalent recipients were identified. The adjusted rVE over a median follow-up of 198 days was 10.9% (6.2%–15.2%) against COVID-19-related hospitalization and 3.2% (1.7%–4.7%) against COVID-19-related outpatient encounters. rVE estimates for COVID-19 hospitalizations among subgroups with comorbid conditions were as follows: diabetes 15.1% (8.7%–21.0%), cerebro- and cardiovascular disease 14.7% (9.0%–20.1%), chronic lung disease 11.9% (5.1%–18.2%), immunocompromised 15.0% (7.2%–22.2%), chronic kidney disease 8.4% (0.5%–15.7%). Conclusions: Overall, among adults with underlying medical conditions, mRNA-1273.222 was more effective than BNT162b2 Bivalent, especially in preventing COVID-19-related hospitalizations.
Keywords: COVID-19; vaccine; mRNA-1273; BNT162b2; high risk; comorbidities; rVE COVID-19; vaccine; mRNA-1273; BNT162b2; high risk; comorbidities; rVE

Share and Cite

MDPI and ACS Style

Kopel, H.; Nguyen, V.H.; Bogdanov, A.; Winer, I.; Boileau, C.; Ducruet, T.; Zeng, N.; Winer-Jones, J.P.; Esposito, D.B.; Bausch-Jurken, M.; et al. Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States. Vaccines 2024, 12, 1107. https://doi.org/10.3390/vaccines12101107

AMA Style

Kopel H, Nguyen VH, Bogdanov A, Winer I, Boileau C, Ducruet T, Zeng N, Winer-Jones JP, Esposito DB, Bausch-Jurken M, et al. Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States. Vaccines. 2024; 12(10):1107. https://doi.org/10.3390/vaccines12101107

Chicago/Turabian Style

Kopel, Hagit, Van Hung Nguyen, Alina Bogdanov, Isabelle Winer, Catherine Boileau, Thierry Ducruet, Ni Zeng, Jessamine P. Winer-Jones, Daina B. Esposito, Mary Bausch-Jurken, and et al. 2024. "Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States" Vaccines 12, no. 10: 1107. https://doi.org/10.3390/vaccines12101107

APA Style

Kopel, H., Nguyen, V. H., Bogdanov, A., Winer, I., Boileau, C., Ducruet, T., Zeng, N., Winer-Jones, J. P., Esposito, D. B., Bausch-Jurken, M., Beck, E., Bonafede, M., & Mansi, J. A. (2024). Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States. Vaccines, 12(10), 1107. https://doi.org/10.3390/vaccines12101107

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop